Comparative Pharmacology
Head-to-head clinical analysis: PAPA DEINE 4 versus WYGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAPA DEINE 4 versus WYGESIC.
PAPA-DEINE #4 vs WYGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: centrally acting analgesic and antipyretic, inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Codeine: opioid agonist, binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain.
WYGESIC (ibuprofen and hydrocodone) combines a nonsteroidal anti-inflammatory drug (ibuprofen) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and a narcotic analgesic (hydrocodone) that acts as a mu-opioid receptor agonist.
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
1-2 tablets (paracetamol 325 mg / tramadol 37.5 mg) orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
None Documented
None Documented
2-4 hours. In hepatic or renal impairment, half-life may increase to 4-6 hours, requiring dose adjustment.
3–4 hours in healthy adults; prolonged to 5–6 hours in moderate renal impairment (CrCl 30–50 mL/min) and >11 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~90% (70% as glucuronide conjugates, 10% as morphine, 10% as normorphine). Biliary/fecal: ~10%.
Primarily renal: 90% as unchanged drug and glucuronide conjugate; <5% fecal.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination